MedTrace Logo

Optimising the Propranolol Block Model

NCT00549120 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-08-04

No results posted yet for this study

Summary

Optimising the propranolol block model

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Propranolol

40 mg tablets

DRUG

Salbutamol

Metered dose inhaler (600 μg)

DRUG

Ipratropium

Metered dose inhaler (40 μg)

DRUG

Placebo

Placebo for propranolol tablets

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-15
Primary Completion
2007-10-26
Completion
2007-10-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00549120 on ClinicalTrials.gov